Targeting the N-methyl-D-aspartate receptor for chronic pain management: Preclinical animal studies, recent clinical experience and future research directions

Journal of Pain and Symptom Management

Volumn 20, Issue 5, 2000, Pages 358-373

  Fisher, Kim ^a   Coderre, Terence J ^c,d   Hagen, Neil A ^a,b,e  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e NONE   (Canada)

Author keywords

Analgesia; Chronic pain; NMDA receptor antagonists; Nociception

Indexed keywords

AMANTADINE; ANALGESIC AGENT; DEXTROMETHORPHAN; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANALGESIC ACTIVITY; CHRONIC PAIN; DRUG DEVELOPMENT; DRUG SAFETY; DRUG TOXICITY; HUMAN; NOCICEPTION; REVIEW;

EID: 0033794460     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00213-X     Document Type: Review

References (197)

1. Glutamate in neurologic diseases
2. Blockade of glutamate excitotoxicity and its clinical applications
3. Excitotoxicity and neurodegenerative diseases
4. Glutamatergic drugs in Parkinson's disease
5. Excitotoxicity in ALS
6. Glutamate receptor antagonists in cerebral ischaemia
7. Excitotoxicity and selective neuronal loss in epilepsy
8. Excitotoxicity and the NMDA receptor-still lethal after eight years
9. Glutamate, excitotoxicity and amyotrophic lateral sclerosis
10. Excitatory amino acids in health and disease
11. Calcium permeability of the channels activated by N-methyl-D-aspartate (NMDA) in isolated mouse central neurones
12. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones
13. The role of postsynaptic calcium in the induction of long-term potentiation
14. 2+ release
15. 2+ of NMDA responses in spinal cord neurones
16. Magnesium gates glutamate activated channels in mouse central neurones
17. Cloned glutamate receptors
18. The glycine site of the NMDA receptor-five years on
19. The glycine site on the NMDA receptor; structure-activity relationships and therapeutic potential
20. Polyamine regulation of N-methyl-D-aspartate receptor channels
21. Interactions of polyamines with neuronal ion channels
22. Modulation of the N-methyl-D-aspartate receptor by polyamines; molecular pharmacology and mechanisms of action
23. Neurochemical aspects of the N-methyl-D-aspartate receptor complex
24. MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy
25. Differential role of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy
26. Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy
27. Systemic ketamine attenuates nociceptive behaviours in a rat model of peripheral neuropathy
28. NMDA receptor antagonists attenuate mechanical hyperalgesia in rats with unilateral inflammation of the hindpaw
29. The effects of a non-competitive NMDA receptor antagonist, MK-801, on behavioral hyperalgesia and dorsal horn neuronal activity in rats with unilateral inflammation
30. The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats
31. Psychotogenicity and N-methyl-D-aspartate receptor antagonism; implications for neuroprotective pharmacotherapy
32. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate
33. An N-methylaspartate receptor-mediated synapse in rat cerebral cortex; a site of action of ketamine
34. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors
35. Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat
36. Preemptive intrathecal ketamine delays mechanical hyperalgesia in the neuropathic rat
37. Preemptive intrathecal ketamine injection produces a long-lasting decrease in neuropathic pain behaviors in a rat model
38. Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat
39. Differential effects of N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists on the responses of rat spinal neurons with joint input
40. The involvement of N-methyl-D-aspartate (NMDA) and non-NMDA receptors in the responsiveness of rat spinal neurons with input from the chronically inflamed ankle
41. N-methyl-D-aspartate receptors mediate responses of rat dorsal horn neurones to hindlimb ischemia
42. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-D-aspartate receptor blockade
43. Response to chronic neuropathic pain syndromes to ketamine; a role for norketamine?
44. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine; a double-blind, cross-over comparison with morphine and placebo
45. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia
46. Successful treatment of postherpetic neuralgia with oral ketamine
47. Four years treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia
48. Analgesic effect of ketamine in a patient with neuropathic pain
49. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine
50. Fibromyalgia-are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs
51. Ketamine in the management of intractable phantom pain
52. The effect of ketamine on phantom pain; a central neuropathic disorder maintained by peripheral input
53. Oral ketamine therapy in the treatment of postamputation stump pain
54. Ketamine hydrochloride in the treatment of phantom limb pain
55. Response of chronic pain syndromes to ketamine; a preliminary study
56. Ketamine injection used orally
57. NMDA receptor blockade in chronic neuropathic pain; a comparison of ketamine and magnesium chloride
58. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain
59. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain
60. Beneficial effect of ketamine in a chronic pain state with allodynia, possibly due to central sensitization
61. The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case
62. Clinical experience with oral ketamine
63. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain
64. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain
65. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation
66. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin; case report
67. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia; a double-blind comparison to alfentanil and placebo
68. Preliminary report on the effect of ketamine in patients with central pain
69. Successful use of ketamine for central pain
70. Ketamine infusion therapy for refractory neuralgia in spinal disease-report of two cases
71. The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans
72. Ketamine; relief from chronic pain through actions at the NMDA receptor?
73. Reply to S.T. Meller; Ketamine: relief from chronic pain through actions at the NMDA receptor
74. The effect of naloxone on hyperalgesia and ketamine-induced side effects in humans
75. Continuous subcutaneous injection of ketamine for cancer pain
76. Subpial vacuolar myelopathy after intrathecal ketamine; report of a case
77. Histological findings after long-term infusion of intrathecal ketamine for chronic pain; a case report
78. Pharmacokinetics and analgesic effects of i.m. and oral ketamine
79. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord
80. Oral ketamine is antinociceptive in the rat formalin test; role of the metabolite, norketamine
81. Dextrorphan and levorphanol selectively block N-methyl-D-aspartate receptor-mediated neurotoxicity on cortical neurons
82. Differential effects of dextrorphan and levorphanol on the excitation of rat spinal neurons by amino acids
83. Selective depression of N-methyl-D-aspartate-mediated responses by dextrorphan in the hippocampal slice in rat
84. 3H]dextrorphan binding in rat brain is localized to noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel
85. 2+ channels
86. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices
87. Dextrorphan relieves neuropathic heat-evoked hyperalgesia in the rat
88. Neuropathic pain sensations are differentially sensitive to dextrorphan
89. Analgesic effect of dextromethorphan for postherpetic neuralgia
90. Dextromethorphan for the treatment of neuropathic pain; a double-blind randomised controlled crossover trial with integral n-of-1 design
91. Dextromethorphan for pain
92. Dextromethorphan and codeine; comparison of plasma kinetics and antitussive effects
93. Pharmacokinetics of dextromethorphan and dextrorphan; a single dose comparison of three preparations in human volunteers
94. Pharmacokinetic comparison of a dextromethorphan-salbutamol combination tablet and a plain dextromethorphan tablet
95. Objective evaluation of dextromethorphan and glaucine as antitussive agents
96. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia
97. High-dose dextromethorphan in amylotrophic lateral sclerosis; Phase I safety and pharmacokinetic studies
98. Dose escalation safety and tolerance study of N-methyl-D-aspartate antagonist dextromethorphan in neurosurgery patients
99. An open label trial of dextromethorphan in Huntington's disease
100. Amantadine in the treatment of Parkinson's disease
101. Amantadine hydrochloride in the treatment of Parkinsonism. A controlled trial
102. Amantadine treatment of Parkinson's disease
103. Use of amantadine in Parkinson's disease. Results of a double-blind trial
104. Amantadine for Parkinson's disease
105. Amantadine hydrochloride in the treatment of Parkinson's disease
106. Amantadine in parkinsonism
107. Amantadine in Parkinson's disease
108. Controlled trial of amantadine hydrochloride in Parkinson's disease
109. Amantadine in Parkinsonism
110. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system; a possible mode of action in Parkinson's disease
111. Amantadine-dopamine interaction; possible mode of action in Parkinsonism
112. Effects of the 1-amino-adamantes at the MK-801-binding site of the NMDA-receptor-gated ion channel; a human postmortem brain study
113. Affinity of 1-aminoadamantanes for the δ binding site in post-mortem human frontal cortex
114. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro
115. Amantadine as N-methyl-D-aspartate receptor antagonist; new possibilities for therapeutic applications?
116. Recurrent herpes simplex sciatica and its treatment with amantadine hydrochloride
117. Improvement of zoster therapy by adamantine
118. Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel)
119. Prevention of post-herpetic neuralgia by amantadine hydrochloride (Symmetrel)
120. Ross River virus polyarthralgia
121. Can patients with chronic neuropathic pain be cured by acute administration of the NMDA receptor antagonist amantadine?
122. The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients; a double blind, randomized, placebo-controlled trial
123. Amanatadine and memantine are NMDA receptor antagonists with neuroprotective properties
124. Clinical pharmacokinetics of amantadine hydrochloride
125. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis
126. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics
127. Amantadine in Parkinson's disease; review of more than two years' experience
128. Anticholinergic effects on memory; benztropine vs. amantadine
129. Results of clinical trials of the antispasmodic agent memantine
130. Efficacy and tolerability of memantine in patients with dementia syndrome
131. Memantine in the treatment of senile dementia of the Alzheimer type
132. Memantine in the treatment of mild to moderate dementia syndrome-a double-blind placebo-controlled study
133. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
134. Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study
135. Trapping channel block of NMDA-activated responses by amantadine and memantine
136. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
137. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
138. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine; therapeutic advantages against NMDA receptor-mediated neurotoxicity
139. 3H]-MK-801 at therapeutic concentrations in postmortem human frontal cortex
140. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
141. Treatment with the NMDA antagonist memantine attentuates nociceptive responses to mechanical stimulation in neuropathic rats
142. The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy
143. Action of 3-((+/-)-2-carboxypiperazin-4-yl)-propyl-1-phosponic acid (CPP); a new and highly potent antagonist of N-methyl-D-aspartate receptors in the hippocampus
144. CPP, a selective N-methyl-D-aspartate (NMDA)-type receptor antagonist; characterization in vitro and in vivo
145. 3H]3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to rat brain membranes; a selective, high-affinity ligand for N-methyl-D-aspartate receptors
146. The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans
147. Magnesium sulphate injected subcutaneously suppresses autotomy in peripherally deafferented rats
148. Magnesium suppresses neuropathic pain responses in rats via a spinal site of action
149. Magnesium sulfate
150. Role of magnesium sulfate in seizure prevention in patients with eclampsia and pre-eclampsia
151. Magnesium sulfate is the ideal anticonvulsant in preeclampsia-eclampsia
152. Intravenous magnesium sulfate rapidly alleviates headaches of various types
153. Pathogenesis of migraine
154. Failure to anesthetize human subjects by intravenous administration of magnesium sulfate
155. Intravenous microdrip infusion of ketamine in subanaesthetic doses for intractable cancer pain
156. Ketamine-its pharmacology and therapeutic uses
157. The chiral forms of ketamine as probes for NMDA receptor functions
158. Interactive effects of subanesthetic ketamine and haloperidol in health humans
159. Comparison of the potency, kinetics and voltage-dependency of a series of noncompetitive NMDA receptor antagonists in vitro with anticonvulsant and motor impairment activity in vivo
160. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine
161. Differences in degree of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block
162. Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity
163. Regional variations in the pharmacology of NMDA receptor channel blockers; implications for therapeutic potential
164. 3H] dextrorphan binding sites in rat brain determined by quantitative autoradiography
165. Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes
166. The molecular basis of NMDA receptor subtypes; native receptor diversity is predicted by subunit composition
167. Cloning and functional chraracterization of human heteromeric N-methyl-D-aspartate receptors
168. Functional characterization of human N-methyl-D-aspartate subtype 1A/2D receptors
169. Stable expression and chracterization of recombinant human heteromeric N-methyl-D-aspartate receptor subtypes NMDAR1A/2A and NMDAR1A/2B in mammalian cells
170. Evidence for native NMDA receptor subtype pharmacology as revealed by differential effects on the NMDA-evoked release of striatal neuromodulators; eliprodil, ifenprodil and other native NMDA receptor subtype selective compounds
171. The pharmacology of native N-methyl-D-aspartate receptor subtypes; different receptors control the release of different striatal and spinal transmitters
172. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats
173. Comparison of ketamine and dextromethorphan in potentiating the antinociceptive effect of morphine in rats
174. Dextromethrophan attenuates and reverses tolerance to morphine
175. Continuous co-administration of dextromethorphan or MK-801 with morphine; attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance
176. Oral administration of dextromethrophan prevents the development of morphine tolerance and dependence in rats
177. Peripheral blockade of topical morphine tolerance by ketamine
178. Low-dose subcutaneous ketamine infusion and morphine tolerance
179. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient
180. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management
181. Tolerability of oral dextromethorphan in patients with a history of brain ischemia
182. Therapeutic brain concentration of the NMDA receptor antagonist amantadine
183. Amantadine in depression; relationship between behavioural effects and plasma levels
184. Amantadine sulphate in treating Parkinson's disease; clinical effects, psychometric tests and serum concentrations
185. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate receptor antagonist memantine in man
186. Sigma and PCP receptors in human frontal cortex membrane
187. 3H]MK-801 binding sites in post-mortem human frontal cortex
188. 3H]MK-801 binding to human hippocampal NMDA receptors
189. Generation and characterisation of stable cell lines expressing recombinant human N-methyl-D-aspartate receptor subtypes
190. N-methyl-D-aspartate receptors; different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents
191. 2+ influx into cells stably expressing recombinant human NMDA receptors by ligands acting at distinct recognition sites